ERBB2 and breast cancer: NRG-BR007 DEBRA (De-Escalation of Breast Radiation) is a currently accruing Phase III prospective, randomized trial evaluating omission of breast radiation in ER+/Her-2 negative early stage breast cancers with Oncotype Recurrence Scores ≤ 18 in women age 50–69 yo [77].